HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel

HTG Molecular Diagnostics (Nasdaq:HTGM) a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first orders to translational and clinical researchers working in the field of cancer immunology and/or cancer immunotherapy.

As quoted in the press release:

“We are thrilled to offer this comprehensive RUO panel. While progress has been made in immuno-therapies, much work still remains on biomarker development to better identify patients who will respond or not respond to these therapies, and we believe our panel, with its 1,392 genes will go a long way in helping reach that goal,” said Mike Hrubiak, Senior Vice President of HTG’s Profiling Business Unit. “We designed this comprehensive assay with input from our scientific advisory panel to further explore areas of immuno-oncology research, including immunophenotyping, tumor inflammation status, and immune-resistance pathways.”

The ability to characterize immune response in tumor environments is believed to be key to developing strategies in recruiting the body’s immune system to recognize and respond to the cancer cells. By using the HTG EdgeSeq Precision Immuno-Oncology Panel, researchers can go from raw sample to sequencing-ready libraries in as little as 36 hours, with less than four hours of hands-on time. HTG is also developing analytic modules to provide researchers with the answers they need when they need them and to provide labs with a complete solution to empower precision medicine at the local level.

Click here to read the full press release.